Exon Array Analysis using re-defined probe sets results in reliable identification of alternatively spliced genes in non-small cell lung cancer

BMC Genomics

Volumn 11, Issue 1, 2010, Pages

  Langer, Wolfram ^a,b   Sohler, Florian ^a   Leder, Gabriele ^a   Beckmann, Georg ^a   Seidel, Henrik ^a   Gröne, Jörn ^c   Hummel, Michael ^c   Sommer, Anette ^a  

^a BAYER PHARMA AG   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADD3 GENE; ALTERNATIVE RNA SPLICING; ANALYTIC METHOD; ARTICLE; BREAST CANCER; CANCER GROWTH; CLSTN1 GENE; CONTROLLED STUDY; EXON; EXON ARRAY ANALYSIS; FN1 GENE; FOX2 GENE; GENE; GENE ACTIVITY; GENE IDENTIFICATION; GENE PROBE; GENETIC DATABASE; GENETIC SCREENING; GENETIC TRANSCRIPTION; GENOME ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; KIAA1217 GENE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; LUNG SQUAMOUS CELL CARCINOMA; MICROARRAY ANALYSIS; MYO18A GENE; NCOR2 GENE; NUMB GENE; OVARY CANCER; RELIABILITY; SLK GENE; SYNE2 GENE; TPM1 GENE; VALIDATION PROCESS; DNA MICROARRAY; DNA PROBE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; LABORATORY DIAGNOSIS; LUNG TUMOR; METABOLISM; METHODOLOGY; REPRODUCIBILITY; TUMOR GENE;

MESSENGER RNA; TUMOR PROTEIN;

ALTERNATIVE SPLICING; CARCINOMA, NON-SMALL-CELL LUNG; DATABASES, GENETIC; DNA PROBES; EXONS; FALSE POSITIVE REACTIONS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; LUNG NEOPLASMS; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER;

EID: 78649491922     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-11-676     Document Type: Article

References (68)

1. NIH, DHHS Cancer Trends Progress Report - 2007 Update. Bethesda, MD 2007, NIH, DHHS., http://progressreport.cancer.gov/
2. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S, Olak J, Stover D, Strawn JR, Turrisi AT, Somerfield MR. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004, 22(2):330-353. 10.1200/JCO.2004.09.053, 14691125.
3. Dempke WCM, Suto T, Reck M. Targeted therapies for non-small cell lung cancer. Lung Cancer 2009, 67(3):257-274. 10.1016/j.lungcan.2009.10.012, 19914732.
4. Müller-Hagen G, Beinert T, Sommer A. Aspects of lung cancer gene expression profiling. Curr Opin Drug Discov Devel 2004, 7(3):290-303.
5. Fichtner I, Rol J, Soong R, Homann J, Hammer S, Sommer A, Becker M, Merk J. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res 2008, 14(20):6456-6468. 10.1158/1078-0432.CCR-08-0138, 18927285.
6. Hammer S, Sommer A, Fichtner I, Becker M, Rol J, Merk J, Klar U, Homann J. Comparative Profiling of the Novel Epothilone, Sagopilone, in Xenografts Derived from Primary Non-Small Cell Lung Cancer. Clin Cancer Res 2010, 16(5):1452-1465. 10.1158/1078-0432.CCR-09-2455, 20179216.
7. Dehan E, Ben-Dor A, Liao W, Lipson D, Frimer H, Rienstein S, Simansky D, Krupsky M, Yaron P, Friedman E, Rechavi G, Perlman M, Aviram-Goldring A, Izraeli S, Bittner M, Yakhini Z, Kaminski N. Chromosomal aberrations and gene expression profiles in non-small cell lung cancer. Lung Cancer 2007, 56(2):175-184. 10.1016/j.lungcan.2006.12.010, 17258348.
8. Smith IM, Glazer CA, Mithani SK, Ochs MF, Sun W, Bhan S, Vostrov A, Abdullaev Z, Lobanenkov V, Gray A, Liu C, Chang SS, Ostrow KL, Westra WH, Begum S, Dhara M, Califano J. Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer. PLoS One 2009, 4(3):e4961. 10.1371/journal.pone.0004961, 2654921, 19305507.
9. Nilsen TW, Graveley BR. Expansion of the eukaryotic proteome by alternative splicing. Nature 2010, 463:457-463. 10.1038/nature08909, 20110989.
10. Matlin AJ, Clark F, Smith CWJ. Understanding alternative splicing: towards a cellular code. Nat Rev Mol Cell Biol 2005, 6(5):386-398. 10.1038/nrm1645, 15956978.
11. Johnson JM, Castle J, Garrett-Engele P, Kan Z, Loerch PM, Armour CD, Santos R, Schadt EE, Stoughton R, Shoemaker DD. Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science 2003, 302(5653):2141-2144. 10.1126/science.1090100, 14684825.
12. Kampa D, Cheng J, Kapranov P, Yamanaka M, Brubaker S, Cawley S, Drenkow J, Piccolboni A, Bekiranov S, Helt G, Tammana H, Gingeras TR. Novel RNAs identified from an in-depth analysis of the transcriptome of human chromosomes 21 and 22. Genome Res 2004, 14(3):331-342. 10.1101/gr.2094104, 353210, 14993201.
13. Venables JP. Unbalanced alternative splicing and its significance in cancer. Bioessays 2006, 28(4):378-386. 10.1002/bies.20390, 16547952.
14. Hayes GM, Carrigan PE, Miller LJ. Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas. Cancer Res 2007, 67(5):2072-2080. 10.1158/0008-5472.CAN-06-2969, 17332336.
15. Ngo JCK, Chakrabarti S, Ding JH, Velazquez-Dones A, Nolen B, Aubol BE, Adams JA, Fu XD, Ghosh G. Interplay between SRPK and Clk/Sty kinases in phosphorylation of the splicing factor ASF/SF2 is regulated by a docking motif in ASF/SF2. Mol Cell 2005, 20:77-89. 10.1016/j.molcel.2005.08.025, 16209947.
16. Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D, Krainer AR. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol 2007, 14(3):185-193. 10.1038/nsmb1209, 17310252.
17. Kim E, Goren A, Ast G. Insights into the connection between cancer and alternative splicing. Trends Genet 2008, 24:7-10. 10.1016/j.tig.2007.10.001, 18054115.
18. Spellman R, Llorian M, Smith CWJ. Crossregulation and functional redundancy between the splicing regulator PTB and its paralogs nPTB and ROD1. Mol Cell 2007, 27(3):420-434. 10.1016/j.molcel.2007.06.016, 1940037, 17679092.
19. Heiner M, Hui J, Schreiner S, Hung LH, Bindereif A. HnRNP L-mediated regulation of mammalian alternative splicing by interference with splice site recognition. RNA Biol 2010, 7:56-64. 10.4161/rna.7.1.10402, 19946215.
20. Akgul C, Moulding DA, Edwards SW. Alternative splicing of Bcl-2-related genes: functional consequences and potential therapeutic applications. Cell Mol Life Sci 2004, 61(17):2189-2199. 10.1007/s00018-004-4001-7, 15338051.
21. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003, 4:33-45. 10.1038/nrm1004, 12511867.
22. Tremmel M, Matzke A, Albrecht I, Laib AM, Olaku V, Ballmer-Hofer K, Christofori G, Héroult M, Augustin HG, Ponta H, Orian-Rousseau V. A CD44v6 peptide reveals a role of CD44 in VEGFR-2 signaling and angiogenesis. Blood 2009, 114(25):5236-5244. 10.1182/blood-2009-04-219204, 19773544.
23. Riechelmann H, Sauter A, Golze W, Hanft G, Schroen C, Hoermann K, Erhardt T, Gronau S. Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncol 2008, 44(9):823-829. 10.1016/j.oraloncology.2007.10.009, 18203652.
24. Castellani P, Viale G, Dorcaratto A, Nicolo G, Kaczmarek J, Querze G, Zardi L. The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer 1994, 59(5):612-618. 10.1002/ijc.2910590507, 7525495.
25. Berndor D, Borkowski S, Sieger S, Rother A, Friebe M, Viti F, Hilger CS, Cyr JE, Dinkelborg LM. Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate. Clin Cancer Res 2005, 11(19 Suppl):7053s-7063s. 10.1158/1078-0432.CCR-1004-0015, 16203802.
26. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100:57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
27. Gardina PJ, Clark TA, Shimada B, Staples MK, Yang Q, Veitch J, Schweitzer A, Awad T, Sugnet C, Dee S, Davies C, Williams A, Turpaz Y. Alternative splicing and differential gene expression in colon cancer detected by a whole genome exon array. BMC Genomics 2006, 7:325. 10.1186/1471-2164-7-325, 1769375, 17192196.
28. Hallegger M, Llorian M, Smith CWJ. Alternative splicing: global insights. FEBS J 2010, 277(4):856-866. 10.1111/j.1742-4658.2009.07521.x, 20082635.
29. Clark TA, Schweitzer AC, Chen TX, Staples MK, Lu G, Wang H, Williams A, Blume JE. Discovery of tissue-specific exons using comprehensive human exon microarrays. Genome Biol 2007, 8(4):R64. 10.1186/gb-2007-8-4-r64, 1896007, 17456239.
30. Zhang W, Duan S, Bleibel WK, Wisel SA, Huang RS, Wu X, He L, Clark TA, Chen TX, Schweitzer AC, Blume JE, Dolan ME, Cox NJ. Identification of common genetic variants that account for transcript isoform variation between human populations. Hum Genet 2009, 125:81-93. 10.1007/s00439-008-0601-x, 2665168, 19052777.
31. Hang X, Li P, Li Z, Qu W, Yu Y, Li H, Shen Z, Zheng H, Gao Y, Wu Y, Deng M, Sun Z, Zhang C. Transcription and splicing regulation in human umbilical vein endothelial cells under hypoxic stress conditions by exon array. BMC Genomics 2009, 10:126. 10.1186/1471-2164-10-126, 2678155, 19320972.
32. Thorsen K, Sørensen KD, Brems-Eskildsen AS, Modin C, Gaustadnes M, Hein AMK, Kruhøer M, Laurberg S, Borre M, Wang K, Brunak S, Krainer AR, Tørring N, Dyrskjøt L, Andersen CL, Orntoft TF. Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis. Mol Cell Proteomics 2008, 7(7):1214-1224. 10.1074/mcp.M700590-MCP200, 18353764.
33. Möller-Levet CS, Betts GNJ, Harris AL, Homer JJ, West CML, Miller CJ. Exon array analysis of head and neck cancers identifies a hypoxia related splice variant of LAMA3 Associated with a poor prognosis. PLoS Comput Biol 2009, 5(11):e1000571. 10.1371/journal.pcbi.1000571, 2773424, 19936049.
34. Xi L, Feber A, Gupta V, Wu M, Bergemann AD, Landreneau RJ, Litle VR, Pennathur A, Luketich JD, Godfrey TE. Whole genome exon arrays identify differential expression of alternatively spliced, cancer-related genes in lung cancer. Nucleic Acids Res 2008, 36(20):6535-6547. 10.1093/nar/gkn697, 2582617, 18927117.
35. Lin E, Li L, Guan Y, Soriano R, Rivers CS, Mohan S, Pandita A, Tang J, Modrusan Z. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res 2009, 7(9):1466-1476. 10.1158/1541-7786.MCR-08-0522, 19737969.
36. Affymetrix Identifying and Validating Alternative Splicing Events. 2006, Affymetrix., http://www.affymetrix.com/support/technical/technotes/id_altsplicingevents_technote.pdf
37. Okoniewski MJ, Hey Y, Pepper SD, Miller CJ. High correspondence between Affymetrix exon and standard expression arrays. Biotechniques 2007, 42(2):181-185. 10.2144/000112315, 17373482.
38. Affymetrix Exon Array Background Correction. 2005, Affymetrix., http://www.affymetrix.com/support/technical/whitepapers/exon_background_correction_whitepaper.pdf
39. Kapur K, Xing Y, Ouyang Z, Wong WH. Exon arrays provide accurate assessments of gene expression. Genome Biol 2007, 8(5):R82. 10.1186/gb-2007-8-5-r82, 1929160, 17504534.
40. Furusawa C, Ono N, Suzuki S, Agata T, Shimizu H, Yomo T. Model-based analysis of non-specific binding for background correction of high-density oligonucleotide microarrays. Bioinformatics 2009, 25:36-41. 10.1093/bioinformatics/btn570, 18977779.
41. Bea CD, Cordero F, Calogero RA. Dissecting an alternative splicing analysis workflow for GeneChip Exon 1.0 ST Affymetrix arrays. BMC Genomics 2008, 9:571. 10.1186/1471-2164-9-571, 2612032, 19040723.
42. Affymetrix Gene Signal Estimates from Exon Arrays. 2005, Affymetrix., http://www.affymetrix.com/support/technical/whitepapers/exon_gene_signal_estimate_whitepaper.pdf
43. Xing Y, Kapur K, Wong WH. Probe selection and expression index computation of Affymetrix Exon Arrays. PLoS ONE 2006, 1:e88. 10.1371/journal.pone.0000088, 1762343, 17183719.
44. Xing Y, Stoilov P, Kapur K, Han A, Jiang H, Shen S, Black DL, Wong WH. MADS: a new and improved method for analysis of differential alternative splicing by exon-tiling microarrays. RNA 2008, 14(8):1470-1479. 10.1261/rna.1070208, 2491471, 18566192.
45. Shah SH, Pallas JA. Identifying differential exon splicing using linear models and correlation coecients. BMC Bioinformatics 2009, 10:26. 10.1186/1471-2105-10-26, 2636774, 19154578.
46. Yates T, Okoniewski MJ, Miller CJ. X:Map: annotation and visualization of genome structure for Affymetrix exon array analysis. Nucleic Acids Res 2008, (36 Database):D780-D786. 2238884, 17932061.
47. Okoniewski MJ, Yates T, Dibben S, Miller CJ. An annotation infrastructure for the analysis and interpretation of Affymetrix exon array data. Genome Biol 2007, 8(5):R79. 10.1186/gb-2007-8-5-r79, 1929135, 17498294.
48. Okoniewski MJ, Miller CJ. Comprehensive analysis of Affymetrix exon arrays using BioConductor. PLoS Comput Biol 2008, 4(2):e6. 10.1371/journal.pcbi.0040006, 2323405, 18463711.
49. Affymetrix Alternative Transcript Analysis Methods for Exon Arrays. 2005, Affymetrix., http://www.affymetrix.com/support/technical/whitepapers/exon_alt_transcript_analysis_whitepaper.pdf
50. Smit AFA, G P, Hubley R. RepeatMasker Open-3.0. 1996, http://www.repeatmasker.org/
51. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000, 132:365-386.
52. Vandesompele J, Preter KD, Pattyn F, Poppe B, Roy NV, Paepe AD, Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002, 3(7):research0034.1-0034.11.
53. Saviozzi S, Cordero F, Iacono ML, Novello S, Scagliotti GV, Calogero RA. Selection of suitable reference genes for accurate normalization of gene expression profile studies in non-small cell lung cancer. BMC Cancer 2006, 6:200. 10.1186/1471-2407-6-200, 1557528, 16872493.
54. Hubbell E, Liu WM, Mei R. Robust estimators for expression analysis. Bioinformatics 2002, 18(12):1585-1592. 10.1093/bioinformatics/18.12.1585, 12490442.
55. Venables JP, Klinck R, Koh C, Gervais-Bird J, Bramard A, Inkel L, Durand M, Couture S, Froehlich U, Lapointe E, Lucier JF, Thibault P, Rancourt C, Tremblay K, Prinos P, Chabot B, Elela SA. Cancer-associated regulation of alternative splicing. Nat Struct Mol Biol 2009, 16(6):670-676. 10.1038/nsmb.1608, 19448617.
56. Baraniak AP, Chen JR, Garcia-Blanco MA. Fox-2 mediates epithelial cell-specific fibroblast growth factor receptor 2 exon choice. Mol Cell Biol 2006, 26(4):1209-1222. 10.1128/MCB.26.4.1209-1222.2006, 1367178, 16449636.
57. Nakahata S, Kawamoto S. Tissue-dependent isoforms of mammalian Fox-1 homologs are associated with tissue-specific splicing activities. Nucleic Acids Res 2005, 33(7):2078-2089. 10.1093/nar/gki338, 1075922, 15824060.
58. Dutertre M, Lacroix-Triki M, Driouch K, de la Grange P, Gratadou L, Beck S, Millevoi S, Tazi J, Lidereau R, Vagner S, Auboeuf D. Exon-Based Clustering of Murine Breast Tumor Transcriptomes Reveals Alternative Exons Whose Expression Is Associated with Metastasis. Cancer Res 2010, 70(3):896-905. 10.1158/0008-5472.CAN-09-2703, 20103641.
59. Raval GN, Bharadwaj S, Levine EA, Willingham MC, Geary RL, Kute T, Prasad GL. Loss of expression of tropomyosin-1, a novel class II tumor suppressor that induces anoikis, in primary breast tumors. Oncogene 2003, 22(40):6194-6203. 10.1038/sj.onc.1206719, 13679858.
60. Okumura M, Kondo S, Ogata M, Kanemoto S, Murakami T, Yanagida K, Saito A, Imaizumi K. Candidates for tumor-specific alternative splicing. Biochem Biophys Res Commun 2005, 334:23-29. 10.1016/j.bbrc.2005.06.057, 16018876.
61. Goodson M, Jonas BA, Privalsky MA. Corepressors: custom tailoring and alterations while you wait. Nucl Recept Signal 2005, 3:e003. 10.1621/nrs.03003, 1402215, 16604171.
62. Yeo GW, Coufal NG, Liang TY, Peng GE, Fu XD, Gage FH. An RNA code for the FOX2 splicing regulator revealed by mapping RNA-protein interactions in stem cells. Nat Struct Mol Biol 2009, 16(2):130-137. 10.1038/nsmb.1545, 2735254, 19136955.
63. Ge X, Yamamoto S, Tsutsumi S, Midorikawa Y, Ihara S, Wang SM, Aburatani H. Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005, 86(2):127-141. 10.1016/j.ygeno.2005.04.008, 15950434.
64. Underwood JG, Boutz PL, Dougherty JD, Stoilov P, Black DL. Homologues of the Caenorhabditis elegans Fox-1 protein are neuronal splicing regulators in mammals. Mol Cell Biol 2005, 25(22):10005-10016. 10.1128/MCB.25.22.10005-10016.2005, 1280273, 16260614.
65. Norris JD, Fan D, Sherk A, McDonnell DP. A negative coregulator for the human ER. Mol Endocrinol 2002, 16(3):459-468. 10.1210/me.16.3.459, 11875103.
66. Romana SP, Radford-Weiss I, Abdelali RB, Schluth C, Petit A, Dastugue N, Talmant P, Bilhou-Nabera C, Mugneret F, Lafage-Pochitalo M, Mozziconacci MJ, Andrieu J, Lai JL, Terre C, Rack K, Cornillet-Lefebvre P, Luquet I, Nadal N, Nguyen-Khac F, Perot C, den Akker JV, Fert-Ferrer S, Cabrol C, Charrin C, Tigaud I, Poirel H, Vekemans M, Bernard OA, Berger R, de Cytogénétique Hématolog GF. NUP98 rearrangements in hematopoietic malignancies: a study of the Groupe Francophone de Cytogénétique Hématologique. Leukemia 2006, 20(4):696-706. 10.1038/sj.leu.2404130, 16467868.
67. Bennett V, Baines AJ. Spectrin and ankyrin-based pathways: metazoan inventions for integrating cells into tissues. Physiol Rev 2001, 81(3):1353-1392.
68. Matsuoka Y, Li X, Bennett V. Adducin: structure, function and regulation. Cell Mol Life Sci 2000, 57(6):884-895. 10.1007/PL00000731, 10950304.